Two articles in the Lancet Neurology report: The most promising Alzheimer's treatment drink
Release date: 2017-11-03
Since he came to MIT to establish his own laboratory in 1970, Professor Rong Xiu and his research team have published more than 1,000 research papers and 200 patents, laying the foundation for many successful medical products. For example, the melatonin product that aids sleep comes from the Richard Wurtman lab.
Today, the latest EU-funded clinical trial results show that a nutritional collocation based on the Wurtman laboratory study has a reliable therapeutic effect on early stage Alzheimer's disease (AD).
Souvenaid
At the beginning of this century, Wurtman developed a cocktail therapy for brain synaptic loss. The mixture increases new synaptic production, restores connectivity between brain regions, and improves memory and cognitive function. A French company and the LipiDiDiet University Alliance (16 European universities and research centers) combined the compound nutrition for this study and created a functional beverage called Souvenaid for AD patients.
Souvenaid has participated in several clinical trials over the years. Although the United States has not officially approved its listing, some countries around the world have already sold Souvenaid as a “medical food†(a regulated safe food designed for disease management).
Lancet Neurology, published October 30, published the latest clinical trial results: patients with pre-existing Alzheimer's disease (pre-dementia stage), taking Souvenaid or placebo. Compared with the control group, patients who drank Souvenaid during the trial period showed a significant decline in disease progression, and daily cognitive and functional manifestations as well as hippocampal atrophy were significantly better than the control group.
“It feels a bit like science fiction, drinking Souvenaid can be more synaptic for you... improving cognitive function,†Wurtman said. "It really works."
Today Souvenaid's inspiring test results are inseparable from MIT's basic research over the years.
When Wurtman Labs explored the mechanisms behind the body's production of phospholipids, Wurtman found that the production of phospholipids relied on a range of nutrient pioneer particles. Specifically, Wurtman is concerned with three natural dietary compounds: choline, uridine, and omega-3 fatty acid DHA.
Choline is widely found in meat, nuts, and eggs. Fish, flaxseed and certain meats contain relatively rich omega-3 fatty acids. Uridine is mainly produced in the liver. Together, these compounds promote the production of phospholipid membranes, which in turn leads to synaptic creation. Known that the disease can continue to reduce brain synapses, Wurtman believes that the use of certain formulas of nutrients can bring hope to diseases related to synaptic loss such as AD.
In 2003, Wurtman attended a conference in Europe. Nutricia (a subsidiary of the Danone Group of France) who attended the event had experience in medical food. As the company is also developing a compound nutrient for the treatment of AD, Wurtman Was invited to the company headquarters to discuss the two cooperation matters.
In 2008, Danone applied for a patent for Souvenaid. The team later found that Souvenaid increased the number of dendritic spines in the brain. When a spine of a neuron contacts a spine of another neuron, a synapse is formed.
The Philip Scheltens team at the Amsterdam Alzheimer's Disease Center in the Journal of Alzheimer's Disease in 2012 issued a document confirming that Souvenaid can improve the language memory of patients with mild AD.
The future of Souvenaid
A recent clinical trial of 24 months with more than 300 participants showed that patients with pre-existing AD taking Souvenaid had a 45% lower cognitive ability than patients taking placebo alone. Surprisingly, Souvenaid significantly reduced the hippocampal volume loss of patients. In the early stages of AD, it plays an important role in memory. Hippocampus often shrinks due to destruction. After taking Souvenaid, the hippocampal deterioration was 26% less than the control group.
"I never even thought that this would happen," Wurtman said. "If you can suppress the loss of the hippocampus, you can better retain cognitive function."
The results show that Souvenaid can slow or stop early AD into the next stage of the disease.
Recently, several early AD diagnostic biomarkers have been identified. However, these biomarkers are useless indicators if there is no means to prevent/treat the disease. "I believe that most people don't do biomarker testing because... the key is that it's useless. Now doctors can tell patients that even if they have early Alzheimer's disease, they can suppress the disease through long-term oral Souvenaid. Developed," Wurtman said.
If prevention/treatment requires only a drink, this may be an important milestone in reversing the treatment of Alzheimer's disease.
Original title
24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial
Source: Biopass
Sesame Products,Black Sesame Seeds Oil,100% Pure Black Sesame Oil,Doypack Sesame Sauce
Chinese Seasoning (Shandong) Trading Co.,Ltd , https://www.zt-trading.com